Document Detail

Bone mineral density of the lumbar spine in very-low-birth-weight infants: a longitudinal study.
MedLine Citation:
PMID:  10664238     Owner:  NLM     Status:  MEDLINE    
CONCLUSION: This study shows that lumbar spinal BMD in VLBW infants can normalize by the age of 2 years.
H Ichiba; H Shintaku; M Fujimaru; C Hirai; Y Okano; M Funato
Related Documents :
24267528 - Ultrasound-guided tunneled lower extremity peripherally inserted central catheter place...
11399448 - The effect of surfactant on birthweight-specific neonatal mortality rate, new york city.
24044478 - Breastfeeding difficulties and exclusivity among late preterm and term infants: results...
23173808 - Delivery at 37 weeks' gestation is associated with a higher risk for child behavioural...
2180378 - Cerebral palsy in very low birthweight infants.
3299568 - Ambroxol in the treatment of idiopathic respiratory distress syndrome. an interim repor...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of pediatrics     Volume:  159     ISSN:  0340-6199     ISO Abbreviation:  Eur. J. Pediatr.     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-04-05     Completed Date:  2000-04-05     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  7603873     Medline TA:  Eur J Pediatr     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  215-8     Citation Subset:  IM    
Department of Pediatrics, Osaka City University Medical School, 1-4-3 Asahimachi, Abenoku, Osaka 545-8586, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Absorptiometry, Photon
Bone Density*
Infant, Newborn
Infant, Very Low Birth Weight / physiology*
Longitudinal Studies
Lumbar Vertebrae / physiology*
Prospective Studies

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recurrent antiphospholipid-related deep vein thrombosis as presenting manifestation of systemic lupu...
Next Document:  Elevation of antibody against Epstein-Barr virus genes BRLF1 and BZLF1 in nasopharyngeal carcinoma.